Yifang Bio-U (688382): Gesulexib is on the market and R&D is progressing smoothly
Yifang Biotech (688382): Focus on the development of high-threshold targeted drugs based on unmet needs
Yifang Bio-U (688382) Investment Value Analysis Report: Biotech, an innovative drug targeting the world from the perspective of pharmaceutical composition
Yifang Biotech (688382): Second domestic production of KRASG12C, a new target for lung cancer
Yifang Bio-U (688382): Befortinib health insurance negotiations are imminent, KRASG12C inhibitor data is excellent, and important cooperation has been reached
Yifang Bio-U (688382) 2023 Three Quarterly Report Review: Befotinib First-line Indications Approved for the Market, KRAS Inhibitor Multiple Indications, Excellent Data on Multiple Indications
Yifang Bio-U (688382): ESMO reads two positive data to focus on the company's catalytic incident
Yifang Biotech (688382): BD with excellent KRAS data combined with a number of R&D advances
Yifang Biotech (688382): Befortinib approved for listing, KRASG12C reached a major cooperation
Yifang Biotech (688382): Published the 2023 semi-annual report, R&D progress is in line with expectations
Yi Fang Biology (688382): D-1553 Domestic Rights Authorization Zhengda Tianqing's multiple products are progressing smoothly
Yifang Biotech (688382): Drugs under development are leading the way in clinical pipeline targeting major indications
Yifang Biotech (688382): Major products are about to be approved, and research pipelines are leading the way
Yi Fang Bio (688382): a BIOTECH rookie with efficient and original global layout
No Data
No Data